Cancers (Nov 2021)
A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy
- Letizia Canu,
- Soraya Puglisi,
- Paola Berchialla,
- Giuseppina De Filpo,
- Francesca Brignardello,
- Francesca Schiavi,
- Alfonso Massimiliano Ferrara,
- Stefania Zovato,
- Michaela Luconi,
- Anna Pia,
- Marialuisa Appetecchia,
- Emanuela Arvat,
- Claudio Letizia,
- Mauro Maccario,
- Mirko Parasiliti-Caprino,
- Barbara Altieri,
- Antongiulio Faggiano,
- Roberta Modica,
- Valentina Morelli,
- Maura Arosio,
- Uberta Verga,
- Micaela Pellegrino,
- Luigi Petramala,
- Antonio Concistrè,
- Paola Razzore,
- Tonino Ercolino,
- Elena Rapizzi,
- Mario Maggi,
- Antonio Stigliano,
- Jacopo Burrello,
- Massimo Terzolo,
- Giuseppe Opocher,
- Massimo Mannelli,
- Giuseppe Reimondo
Affiliations
- Letizia Canu
- Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, 50139 Florence, Italy
- Soraya Puglisi
- Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, Orbassano, 10043 Turin, Italy
- Paola Berchialla
- Statistical Unit, Department of Clinical and Biological Sciences, University of Turin, Orbassano, 10143 Turin, Italy
- Giuseppina De Filpo
- Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, 50139 Florence, Italy
- Francesca Brignardello
- Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, Orbassano, 10043 Turin, Italy
- Francesca Schiavi
- Familial Cancer Clinic, Veneto Institute of Oncology IOV – IRCCS, 35128 Padua, Italy
- Alfonso Massimiliano Ferrara
- Familial Cancer Clinic, Veneto Institute of Oncology IOV – IRCCS, 35128 Padua, Italy
- Stefania Zovato
- Familial Cancer Clinic, Veneto Institute of Oncology IOV – IRCCS, 35128 Padua, Italy
- Michaela Luconi
- Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, 50139 Florence, Italy
- Anna Pia
- Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, Orbassano, 10043 Turin, Italy
- Marialuisa Appetecchia
- Oncological Endocrinology Unit, IRCCS-Regina Elena National Cancer Institute, 00128 Rome, Italy
- Emanuela Arvat
- Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy
- Claudio Letizia
- Secondary Arterial Hypertension Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, 00161 Rome, Italy
- Mauro Maccario
- Endocrinology, Diabetology, and Metabolism Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy
- Mirko Parasiliti-Caprino
- Endocrinology, Diabetology, and Metabolism Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy
- Barbara Altieri
- Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, 97080 Würzburg, Germany
- Antongiulio Faggiano
- Endocrinology, Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, Sapienza University of Rome, 00189 Rome, Italy
- Roberta Modica
- Division of Endocrinology, Department of Clinical Medicine and Surgery, ENETS Center of Excellence, University “Federico II” of Naples, 80138 Naples, Italy
- Valentina Morelli
- Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy
- Maura Arosio
- Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy
- Uberta Verga
- Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy
- Micaela Pellegrino
- Division of Endocrinology, Diabetology and Metabolism, Santa Croce and Carle Hospital, 12100 Cuneo, Italy
- Luigi Petramala
- Secondary Arterial Hypertension Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, 00161 Rome, Italy
- Antonio Concistrè
- Secondary Arterial Hypertension Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, 00161 Rome, Italy
- Paola Razzore
- Endocrinology, Diabetology and Metabolism Diseases Unit, AO Ordine Mauriziano, 10128 Turin, Italy
- Tonino Ercolino
- Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, 50134 Florence, Italy
- Elena Rapizzi
- Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, 50134 Florence, Italy
- Mario Maggi
- Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, 50139 Florence, Italy
- Antonio Stigliano
- Endocrinology, Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, Sapienza University of Rome, 00189 Rome, Italy
- Jacopo Burrello
- Division of Internal Medicine and Hypertension Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy
- Massimo Terzolo
- Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, Orbassano, 10043 Turin, Italy
- Giuseppe Opocher
- Veneto Institute of Oncology, IRCCS, 35128 Padua, Italy
- Massimo Mannelli
- Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, 50139 Florence, Italy
- Giuseppe Reimondo
- Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, Orbassano, 10043 Turin, Italy
- DOI
- https://doi.org/10.3390/cancers13225831
- Journal volume & issue
-
Vol. 13,
no. 22
p. 5831
Abstract
No studies have carried out an extensive analysis of the possible association between non-syndromic pheochromocytomas and paragangliomas (PPGLs) and other malignancies. To assess >the risk of additional malignancy in PPGL, we retrospectively evaluated 741 patients with PPGLs followed-up in twelve referral centers in Italy. Incidence of second malignant tumors was compared between this cohort and Italian patients with two subsequent malignancies. Among our patients, 95 (12.8%) developed a second malignant tumor, which were mainly prostate, colorectal and lung/bronchial cancers in males, breast cancer, differentiated thyroid cancer and melanoma in females. The standardized incidence ratio was 9.59 (95% CI 5.46–15.71) in males and 13.21 (95% CI 7.52–21.63) in females. At multivariable analysis, the risk of developing a second malignant tumor increased with age at diagnosis (HR 2.50, 95% CI 1.15–5.44, p = 0.021 for 50–59 vs. p 60- vs. p = 0.003). In conclusion, PPGLs patients have higher incidence of additional malignant tumors compared to the general population who had a first malignancy, which could have an impact on the surveillance strategy.
Keywords
